Amphastar Pharmaceuticals Inc (NASDAQ: AMPH) has reported E.P.S. of $0.77 for its second fiscal quarter (ending June 30) versus $0.54 for the same period a year ago — an increase of 43%. Relative to the consensus estimate of $0.75, this was a premium of $0.02. For the latest four quarters through June 30, E.P.S. were $3.43 compared to $2.10 a year ago — an increase of 63%.
Recent Price Action
Amphastar Pharmaceuticals Inc (NASDAQ: AMPH) stock declined modestly by -1.3% on 8/7/24. The stock closed at $38.89. Moreover, this decline was accompanied by above average trading volume at 120% of normal. The stock has been extremely weak relative to the market over the last nine months and has declined -10.6% during the last week.
Current PriceTarget Research Rating
AMPH is expected to continue to be a major Value Builder reflecting capital returns that are forecasted to be above the cost of capital.
Amphastar Pharmaceuticals has a current Value Trend Rating of C (Neutral). This rating combines contradictory signals from two proprietary PTR measures of a stock’s attractiveness. Amphastar Pharmaceuticals has a slightly positive Appreciation Score of 64 but a poor Power Rating of 24, with the Neutral Value Trend Rating the result.
Rating Review
In light of this new information and negative market action we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment